



Narrative review

How to: Surveillance of *Clostridium difficile* infections

M. Krutova^{1,7,*}, P. Kinross², F. Barbut^{3,7}, A. Hajdu⁴, M.H. Wilcox^{5,7}, E.J. Kuijper^{6,7},
The survey contributors[†]

¹ Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic

² Surveillance and Response Support Unit, European Centre for Disease Prevention and Control, Stockholm, Sweden

³ National Reference Laboratory for *C. difficile*, Hôpital Saint-Antoine, Paris, France

⁴ Department of Hospital Hygiene and Communicable Disease Control, Ministry of Human Capacities, Budapest, Hungary

⁵ Leeds Teaching Hospitals NHS Trust & University of Leeds, Leeds, United Kingdom

⁶ Department of Medical Microbiology, Leiden University Medical Centre, Leiden, The Netherlands

⁷ European Society of Clinical Microbiology and Infectious Diseases (ESCMID) study group for *Clostridium difficile* (ESGCD)

ARTICLE INFO

Article history:

Received 29 September 2017

Received in revised form

9 December 2017

Accepted 13 December 2017

Available online 20 December 2017

Editor: L. Leibovici

Keywords:

Clostridium difficile

Clostridium difficile typing

Clostridium difficile infection

Clostridium difficile infection epidemiology

Healthcare-associated infection

ABSTRACT

Background: The increasing incidence of *Clostridium difficile* infections (CDI) in healthcare settings in Europe since 2003 has affected both patients and healthcare systems. The implementation of effective CDI surveillance is key to enable monitoring of the occurrence and spread of *C. difficile* in healthcare and the timely detection of outbreaks.

Aims: The aim of this review is to provide a summary of key components of effective CDI surveillance and to provide some practical recommendations. We also summarize the recent and current national CDI surveillance activities, to illustrate strengths and weaknesses of CDI surveillance in Europe.

Sources: For the definition of key components of CDI surveillance, we consulted the current European Society of Clinical Microbiology and Infectious Diseases (ESCMID) CDI-related guidance documents and the European Centre for Disease Prevention and Control (ECDC) protocol for CDI surveillance in acute care hospitals. To summarize the recent and current national CDI surveillance activities, we discussed international multicentre CDI surveillance studies performed in 2005–13. In 2017, we also performed a new survey of existing CDI surveillance systems in 33 European countries.

Content: Key components for CDI surveillance are appropriate case definitions of CDI, standardized CDI diagnostics, agreement on CDI case origin definition, and the presentation of CDI rates with well-defined numerators and denominators. Incorporation of microbiological data is required to provide information on prevailing PCR ribotypes and antimicrobial susceptibility to first-line CDI treatment drugs. In 2017, 20 European countries had a national CDI surveillance system and 21 countries participated in ECDC-coordinated CDI surveillance. Since 2014, the number of centres with capacity for *C. difficile* typing has increased to 35 reference or central laboratories in 26 European countries.

Implications: Incidence rates of CDI, obtained from a standardized CDI surveillance system, can be used as an important quality indicator of healthcare at hospital as well as country level. **M. Krutova, Clin Microbiol Infect 2018;24:469**

© 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Background

Clostridium difficile, recently reclassified as *Clostridioides difficile*, is a Gram-positive spore-forming ubiquitous bacterium [1]. Toxigenic strains can cause *C. difficile* infection (CDI) with diverse clinical

manifestations ranging from mild diarrhoea to life-threatening conditions. The most important modifiable risk factor for CDI is previous antibiotic treatment [2]. European data on CDI epidemiology in acute healthcare derive from a few limited studies with significant differences in their study design and number of participating healthcare facilities [3–7]. In response to an increased CDI incidence and spread of epidemic *C. difficile* strains belonging to ribotype (RT) 027 in Europe since 2003 [2–4], the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) published guidance documents for CDI diagnostics, treatment and infection control [8–10].

* Corresponding author. M. Krutova, Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06 Prague 5, Czech Republic.

E-mail address: marcela.krutova@lfmotol.cuni.cz (M. Krutova).

† See Acknowledgements

In May 2015, the European Centre for Disease Prevention and Control (ECDC) published a protocol for hospital-based CDI surveillance, to support the implementation of standardized CDI surveillance in Europe [11], in advance of the start of ECDC-coordinated surveillance of CDI on 1 January 2016.

The objectives of standardized CDI surveillance are to estimate the incidence and burden of CDI and to acquire information on the outcome of CDI, including deaths.

The purpose of this review is to provide a summary of key components of effective CDI surveillance and to provide some practical suggestions. We also summarize the recent and current national CDI surveillance activities, to illustrate strengths and weaknesses of CDI surveillance in Europe.

How to define a CDI case?

The alertness of clinicians to CDI and the availability of laboratory diagnostics with appropriate algorithms fundamentally affect CDI surveillance data. ESCMID currently recommends the systematic testing of patients with antibiotic-associated or healthcare-associated diarrhoea [8]. CDI surveillance is commonly restricted to hospitalized patients in the acute healthcare setting, even though several studies have highlighted the importance of CDI in long-term non-acute care, nursing homes and in the community [12,13].

According to available guidance, microbiology laboratories should consider performing tests for CDI on all unformed stools (i.e. those that take the shape of the container) from healthcare settings such as acute care hospitals, irrespective of the request from the physician [5,8]. Solid stool samples should not be tested because of the absence of diarrhoea and the possibility of detecting asymptomatic *C. difficile* carriage. Rectal swabs should be used to acquire laboratory samples from patients with ileus due to reduced peristalsis [8]. Unless there is a strong clinical indication, unformed stool samples from children <2 years of age should not be tested, because asymptomatic gastrointestinal carriage is relatively common in this age group [14,15]. Test-of-cure should be discouraged, as it is possible to have prolonged carriage of *C. difficile*, despite the resolution of diarrhoea [8].

Since 2009, ESCMID has recommended a two-step algorithm for microbiological diagnosis of CDI [8]. The first step should be a sensitive test with a high negative predictive value. These should either be an enzyme immunoassay for the detection of glutamate

dehydrogenase, or a nucleic acid amplification test for the detection of *C. difficile* toxin gene(s). When this screening test is positive, stool samples should be tested using a sensitive enzyme immunoassay or a cell cytotoxicity neutralization assay in a second step, to confirm the presence of free toxins in the stool samples. The use of stand-alone enzyme immunoassays for toxins should be discouraged because of their insufficient sensitivity. Stand-alone nucleic acid amplification tests, which detect the presence of toxin genes, can overestimate the incidence of CDI, because they do not detect *in vivo* toxin production [8,16].

Patients who have had pseudomembranous colitis diagnosed by lower gastrointestinal endoscopy, or who have characteristic colonic histopathology, should also be considered to be a CDI case, without any further requirement for stool sample testing [11,17,18]. However, pseudomembranous colitis is not entirely specific for CDI. Other pathogens (e.g. cytomegalovirus, *Entamoeba histolytica*, *Shigella* species, Shiga-toxin producing *Escherichia coli*) and medication (e.g. cisplatin, cyclosporine A) can cause similar pathology [19].

A decision algorithm for application of the CDI case definition using ESCMID-recommended diagnostic algorithm [8] is shown in Fig. 1a.

CDI case origin

The designation of case origin is determined by the time and place of the onset of CDI symptoms [2,11,17,18,20], (Fig. 1b).

Cases of 'healthcare-associated CDI' (HA CDI) either had an onset of symptoms in a healthcare facility on day three or later, following admission to a healthcare facility on day one; or they had onset in the community within 4 weeks of discharge from a healthcare facility (the current facility or any other facility).

'Community-associated CDI' (CA CDI) cases have had no discharge from a healthcare facility within the 12 weeks before the onset of symptoms. In addition, their onset of symptoms either took place outside healthcare facilities, or took place in a healthcare facility on the day of admission or on the following day.

If a CDI case has been discharged from a healthcare facility in the 4–12 weeks before the onset of their CDI symptoms, their case origin is designated as 'unknown'.

The designation of a CDI case as 'recurrent' is independent of the designation of CDI case origin. Recurrent CDI cases are individuals who meet the CDI case definition (including return of diarrhoeal




Fig. 1. Decision algorithms for (a) application of *Clostridium difficile* infection (CDI) case definition using ESCMID-recommended diagnostic algorithm [8] and (b) designation of the origin of CDI cases.

stools with a positive laboratory test) after completion of CDI treatment, who had new onset of symptoms between 2 and 8 weeks after the onset of symptoms from a previous episode of CDI.

CDI rates

Presentation of CDI rates as incidence density (cases/10 000 patient-days) or incidence (cases/10 000 admissions) facilitates comparison of hospitals of different sizes with different surveillance periods. If data on the number of patient-days or number of admissions are unavailable, suitable alternative denominators include bed-days (cases/10 000 bed-days) and discharges (cases/10 000 discharges). Patient-days are calculated by summing the number of days in which a bed is occupied overnight by patients hospitalized during the surveillance period. Bed-days are calculated by multiplying the number of hospital beds by the length of the surveillance period of that hospital.

All hospitalized patients should be included in the denominator, including patients on long-term care wards and children aged ≤ 2 years. Day patients should be excluded, i.e. hospital patients who arrive and leave without an overnight stay, such as day cases, emergency room patients and dialysis patients [11,17,18].

The numerator is the number of hospitalized patients who meet the CDI case definition who had their onset of CDI symptoms during the surveillance period, plus the number of CDI cases who were admitted during the surveillance period with CDI symptom present at admission. *C. difficile*-positive children aged ≤ 2 years should only be included in the numerator if there is a compelling clinical evidence to diagnose them as a CDI case [11,17,18].

C. difficile isolate characterization for surveillance purposes

Laboratory methods to characterize *C. difficile* isolates include PCR ribotyping, detection of the presence of toxin genes or toxin production and antimicrobial susceptibility testing. Preferably, typing should be performed at a national reference or central laboratory.

Polymerase chain reaction (PCR) ribotyping is a molecular typing method based on variability in a length and number of copies of intergenic spacer region between genes encoding 16S and 23S ribosomal RNA. Capillary electrophoresis-based PCR ribotyping has higher discriminatory power, which enables inter-laboratory data exchange, than conventional agarose-based ribotyping [21]. Four national reference centres in Europe and North America recently validated a published laboratory protocol for capillary electrophoresis PCR ribotyping, which has high inter-laboratory reproducibility [22].

Different *C. difficile* RTs (strains) may produce different spectra of toxins (toxin A, toxin B and binary toxin), whereas non-toxigenic RTs (strains) do not encode the genes for toxin production. Current protocols for multiplex PCR determine the presence of such *C. difficile* virulence factors (e.g. *tcdA*, *tcdB*, *cdtA* and *cdtB*) [23,24], although ultimately such data should also be obtainable from whole genome sequencing.

For the purpose of CDI surveillance, determination of antimicrobial susceptibility to metronidazole, vancomycin and moxifloxacin is recommended, using European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints [11,17,18,25]. Fidaxomicin susceptibility testing should also be considered, especially in countries that include fidaxomicin in their CDI treatment recommendations. EUCAST specifies that the MIC breakpoints for metronidazole and vancomycin are 2 mg/L, whereas the MIC for moxifloxacin is 4 mg/L. These EUCAST breakpoints are based on epidemiological cut-off values that distinguish

wild-type isolates from those with reduced susceptibility [25]. No epidemiological cut-off value has been determined for fidaxomicin yet, but two European studies suggest a MIC of 0.25 mg/L [26,27]. Agar dilution is recommended for antimicrobial susceptibility testing [25], particularly if it is performed by a national or central reference laboratory. Other methods, such as E-test and CLSI agar incorporation, may not recognize isolates with reduced susceptibility to metronidazole [28].

Incorporation of whole genome sequencing data into CDI surveillance could markedly improve epidemiological investigations of CDI transmission. Whole genome sequencing data have already been applied to the analysis of transmission chains of *C. difficile* between patients [29–31] and between humans and animals [32]. In addition, genomic data have been used for phylogenetic studies of epidemic RT017 and RT027 [33,34].

Summary of CDI epidemiology in Europe until 2017

Several European multicentre studies have been performed to describe CDI epidemiology and to estimate CDI prevalence and incidence in Europe. In 2000, CDI incidence was estimated to be 1.1 cases per 1000 patient admissions [35]. In 2005, the incidence density was estimated at 2.5 cases per 10 000 patient-days [3]. In 2008, CDI incidence was estimated at 4.1 cases per 10 000 patient-days [4]. In 2011–13, a prospective, multicentre, biannual, point prevalence study of CDI in hospitalized patients with diarrhoea (EUCLID) estimated an incidence density of 7.0 cases per 10 000 patient-days [5]. The increased CDI incidence rates reported in the EUCLID study are probably associated with the study design using an optimal testing algorithm. This study also provided strong evidence that CDI incidence was underestimated in Europe, due to a lack of awareness for *C. difficile* testing among physicians [5]. The 2011/12 ECDC point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals included data from >230 000 patients in 33 European countries. The prevalence of HA CDI was 3.7%. It estimated that the burden of HA CDI was 123 997 (95% CI 61 018–284 857) cases annually in the European Union and European Economic Area (EU/EEA) countries [36].

The observed increase in CDI incidence has been concomitant with changes in the prevailing *C. difficile* RTs in Europe. The predominance of RT001 (13%) and RT014/020 (16%) in 2005 and 2008, respectively [3,4], was displaced by a predominance of RT027 (19%) by 2012/13 [6]. The emergence of RT027 significantly influenced CDI surveillance policy worldwide, due to its outbreak potential and association with notable morbidity and mortality [2,37,38]. For an overview of results from international multicentre CDI studies in Europe see Supplementary material (Table S1).

In 2011/12 in Europe, the emergence of reduced susceptibility to metronidazole and vancomycin and almost 40% resistance to moxifloxacin was observed among the most prevalent European RTs of 953 *C. difficile* isolates tested [26]. A recent study suggests that variations in the rate of fluoroquinolone prescription may have been a major factor in the emergence, and later for the control, of CDI due to fluoroquinolone-resistant *C. difficile* RTs including RT027 in England [39].

ECDC-coordinated CDI surveillance in the EU/EEA

The ECDC surveillance protocol for European surveillance of CDI derives from the protocol produced as part of the ECDC-funded 'European CDI Surveillance Network' (ECDIS-Net) project [7]. The protocol specifies three options for surveillance intensity: the 'minimal option' that only collects hospital-level aggregate numerators and denominators, the 'light option' that also collects case-based numerators including mortality, and the 'enhanced

option' that also collects microbiological data on at least the first ten cases with a unique identifier linking the case-based data [11], (Table 1).

Fourteen European countries pilot tested the ECDC protocol, including five countries that did not have ongoing national CDI surveillance. Thirty-seven hospitals participated and collected data for 90–92 days between 13 May and 1 November 2013. Thirty-six hospitals included all wards and one hospital excluded the neonatal ward. All hospitals used the minimal and light surveillance options; the enhanced option was used by 33 hospitals. Data were collected for 1152 individuals, of which 1078 also had case-based data collected using the light or enhanced option. CDI origin and infection outcome data were available for 1013 (94%) and 1056 (98%) of these individuals, respectively. Of the 317 individuals for whom enhanced data were collected, 291 (92%) had a successful match of their microbiological and epidemiological data. Additionally, the coordinating laboratory could assign an RT to 268 (92%) of the 291 isolates collected from these individuals [7].

A post-pilot survey regarding the feasibility of the three surveillance options was completed by 26 (79%) of 33 hospitals. They reported that data collection was 'not difficult' for both the light option (88% hospitals) and the enhanced option (enhanced case-based data: 88%; microbiological data collection: 92%). The median times required for the minimal, light and enhanced protocols were 1.1, 2.0 and 3.0 person-days per 10 000 discharges, respectively [7].

ECDC coordination of CDI surveillance in EU/EEA countries started on 1 January 2016. During the first year of surveillance, hospitals in at least 21 (70%) of 30 EU/EEA countries used the common protocol to acquire comparable CDI surveillance data [40,41].

As of 6 December 2017, 19 countries had submitted CDI surveillance data to ECDC, for 579 hospital surveillance periods in 2016. Of these hospital surveillance periods, 294 (50.8%) had used the enhanced surveillance option, 54 (9.3%) had used the light surveillance option and 231 (39.9%) had used the minimal surveillance option.

The current protocol (version 2.3 from April 2017) requests microbiological data (enhanced option) from at least five consecutive CDI cases, whereas previous protocol versions (versions 2.1 and 2.2) had requested data from ten consecutive isolates [11,17,18]. There is currently no evidence base for the minimum number of isolates; rather the recommendations were designed to promote feasibility. Notably, a study in 21 hospitals in the Czech Republic in 2015 identified a difference in the distribution of RTs detected in the first ten and the second ten consecutive *C. difficile* isolates within each hospital [42]. Some countries, such as the Netherlands, perform comprehensive surveillance of all CDI cases, collecting

epidemiological, clinical and microbiological data. This supports early recognition of outbreaks due to new *C. difficile* RTs and the distribution of certain RTs in specific populations [43,44]. As the ECDC protocol links microbiological data to case data, the hospitals' collection and reporting of microbiological data from all their cases will permit faster identification of new strains with increased morbidity or mortality, thus facilitating initiation of appropriate control measures.

To support the microbiological aspects of ECDC CDI surveillance, the Leiden University Medical Centre, the Netherlands, provides reference typing of *C. difficile* isolates that are not typeable at national level in EU/EEA countries, in close collaboration with the *C. difficile* reference laboratory in Leeds, UK (open call for tender OJ/05/11/2015-PROC/2015/029, framework service contract ECDC/2016/016).

Survey of current CDI surveillance systems in Europe

In August 2017, to update the current knowledge on CDI surveillance in Europe, the ESCMID study group for *C. difficile* (ESGCD) conducted a survey by sending a questionnaire to selected subject-matter experts from EU Member States, Iceland, Norway and Switzerland. For the UK, representatives from England, Northern Ireland, Wales and Scotland were contacted separately. The questionnaire requested information on existing CDI surveillance systems and availability of reference laboratories for *C. difficile* in their country. The survey was completed by 33 out of 34 countries (see Supplementary material, Table S2).

In this ESGCD survey, 20 of 33 countries reported 24 national CDI surveillance systems (Fig. 2). This is more than was reported in a similar survey in 2011, when a CDI surveillance system was in place in only 14 of the 31 responding European countries [20].

Many of the 24 national surveillance systems report data on only HA CDI, even though CA CDI and 'unknown origin' CDI constituted 16% of CDIs detected in hospitalized patients during the pilot survey of European CDI surveillance in 2013 [7]. National surveillance systems in the Netherlands and Hungary changed in 2011 and 2015, respectively, to provide data on the origin of CDI cases in hospitalized patients, rather than solely reporting data on HA CDI.

In 2017, 26 of 33 countries reported the existence of a national reference or central laboratory for *C. difficile* in their country, indicating the availability of support for the enhanced option of the ECDC CDI surveillance protocol (Fig. 2). The reference laboratories of 11 countries produced an annual CDI report.

Polymerase chain reaction ribotyping was available for CDI surveillance in 20 of 31 countries in 2011 and 23 of 32 countries in 2014 [45]. The current survey indicates that two of nine countries

Table 1

Data collected in the three different *Clostridium difficile* infection (CDI) surveillance options in the ECDC CDI surveillance protocol [11,17,18]

	Surveillance option		
	Minimal	Light	Enhanced
CDI cases			
Healthcare-associated, community-associated, unknown association; recurrent cases	✓	✓	✓
CDI testing frequency			
Number of stool specimens tested for CDI; number that tested positive for CDI	✓	✓	✓
Hospital denominators			
Number of beds, discharges/admissions and patient-bed days	✓	✓	✓
Laboratory algorithm used for CDI diagnosis	✓	✓	✓
CDI case based data			
Age, sex, previous hospitalization, CDI case origin, patient outcome including attributable mortality	x	✓	✓
Microbiological data on <i>C. difficile</i> isolates			
Ribotype, presence of toxins/toxin genes, antimicrobial susceptibility testing	x	x	✓




Fig. 2. The presence of *Clostridium difficile* infection surveillance system and reference or central laboratories for *C. difficile* in 2017, by country.

that did not have any ribotyping available in 2014 have acquired capacity for capillary electrophoresis PCR ribotyping (Slovakia and Greece). In our 2017 survey, 13 countries reported the availability of multilocus variable-number tandem-repeats analysis, which is particularly suitable for outbreak investigation [46–48].

Future perspectives

The incidence of HA CDI is an important quality indicator of healthcare at hospital as well as country level, reflecting the quality of both infection prevention and control as well as antimicrobial stewardship. Results from this ESGCD survey indicate progress across Europe towards comprehensive monitoring and reporting of CDI, including provision of detailed microbiological data on circulating *C. difficile* strains.

There are still options to improve the epidemiological and microbiological aspects of CDI surveillance. For example, linkage of CDI surveillance data to antimicrobial and proton pump inhibitor consumption data at hospital or national level, using existing national and European databases, may be useful to assess the impact of antimicrobial use and proton pump inhibitor use on CDI incidence [49]. Additionally, CA CDI is usually only detected if the patient attends healthcare and is tested for CDI. Monitoring of CA CDI at national and European level should permit the determination of CDI incidence in community and identification of prevailing RTs.

Availability of CDI surveillance data in ‘real time’ could be achieved by implementation of electronic surveillance. Linkage of hospital administrative information systems to microbiological information systems will eventually permit automated reporting of CDI data, enabling rapid identification of outbreaks. Until electronic

surveillance is achievable, frequent reporting of CDI surveillance data at national and European level should be promoted, in close collaboration with ECDC.

Published data suggest an increase in CDI incidence in Europe and rapid changes in the distribution of the most prevalent RTs [5,6,34,40–42]. This calls for the strengthening of national and European centres to provide up-to-date diagnostic, prevention and treatment advice for CDI. Such centres could also provide molecular typing support for CDI outbreaks in healthcare facilities. Typing (e.g. PCR ribotyping and eventually whole genome sequencing) data should optimally be shared within a European network, to enable early identification of emergent RTs with public health relevance.

Transparency declaration

All authors report no conflict of interest relevant to this article. No financial support was received for this study.

Acknowledgements

We would like to thank all members of the ESCMID study group for *Clostridium difficile* (ESGCD) for their participation in previous studies and especially thank the experts who contributed to this survey on CDI surveillance in Europe.

The survey contributors.

F. Allerberger (AGES, Vienna, Austria), M. Delmée and J. Van Broeck (Catholic University of Louvain, Brussels, Belgium), R. Vatcheva-Dobrevska (University Hospital ‘Queen Joanna’, Sofia, Bulgaria), E. Dobrev (National Centre of Infectious and Parasitic

Diseases, Sofia, Bulgaria), B. Matica (Andrija Stampar Teaching Institute of Public Health, Zagreb, Croatia), D. Pieridou (Nicosia General Hospital, Nicosia, Cyprus), M. Krutová and O. Nyč (Motol University Hospital, Prague, Czech Republic), B. Olesen (Herlev and Gentofte Hospital, University of Copenhagen, Denmark), P. Märtin (Health Board, Tallinn, Estonia), S. Mentula (Institute of Health and Welfare, Helsinki, Finland), F. Barbut (Saint-Antoine Hospital, Paris, France), M. Arvand (Robert Koch Institute, Berlin, Germany), L. von Müller (Christophorus Kliniken, Coesfeld, Germany), J. Papaparaskevas (National and Kapodistrian University of Athens, Greece), J. Pászti (National Public Health Institute, Budapest, Hungary), Á. Hajdu (Ministry of Human Capacities, Budapest, Hungary), T. Gudnason (Centre for Health Security and Communicable Disease Control, Reykjavík, Iceland), K. Burns (Health Protection Surveillance Centre & Beaumont Hospital, Dublin, Ireland), P. Spigaglia (Istituto Superiore di Sanità, Rome, Italy), K. Vulane (Centre for Disease Prevention and Control, Riga, Latvia), M. Debacker (Le Gouvernement du Grand-Duché de Luxembourg, Direction de la Santé, Luxembourg), E. Scicluna and T. Melillo (Infectious Disease Prevention and Control Unit, Mater Dei Hospital, Msida, Malta), E.J. Kuijper and M.T. Crobach (Leiden University Medical Centre, Leiden, the Netherlands), O. Kacelnik and E. Astrup (Norwegian Institute of Public Health, Oslo, Norway), H. Pituch (Medical University of Warsaw, Poland), M. Oleastro (National Institute of Health Dr Ricardo Jorge, Lisboa, Portugal), C. Wiuff (Health Protection Scotland, Glasgow, UK), J. Coia (Scottish Microbiology Reference Laboratories, Glasgow, UK), E. Nováková (Comenius University Jessenius Faculty of Medicine in Martin, Slovakia), J. Kolman and E. Grilc (National Institute of Public Health, Ljubljana, Slovenia) and M. Rupnik (National laboratory for health, environment and food, NLZOH, Maribor, Slovenia), E. Bouza and E. Reigadas (University Hospital Gregorio Marañón, Madrid, Spain), T. Åkerlund (Public Health Agency of Sweden, Solna, Sweden), S. Tschudin-Sutter (University Hospital, Basel, Switzerland), M.H. Wilcox (Leeds Teaching Hospitals NHS Trust, Leeds, UK), D. Fairley (Belfast Health & Social Care Trust, Belfast, UK), T. Morris (UK Anaerobe Reference Unit, Public Health Wales, UK).

Appendix A. Supplementary data

Supplementary data related to this article can be found at <https://doi.org/10.1016/j.cmi.2017.12.008>.

References

- [1] Lawson PA, Citron DM, Tyrrell KL, Finegold SM. Reclassification of *Clostridium difficile* as *Clostridioides difficile* (Hall and O'Toole 1935) Prévot 1938. *Anaerobe* 2016;40:95–9.
- [2] Kuijper EJ, Coignard B, Tüll P, ESCMID Study Group for *Clostridium difficile*. EU Member States, European Centre for Disease Prevention and Control. Emergence of *Clostridium difficile*-associated disease in North America and Europe. *Clin Microbiol Infect* 2006;12:2–18.
- [3] Barbut F, Mastrantonio P, Delmée M, Brazier J, Kuijper E, Poxton I, European Study Group on *Clostridium difficile* (ESGCD). Prospective study of *Clostridium difficile* infections in Europe with phenotypic and genotypic characterisation of the isolates. *Clin Microbiol Infect* 2007;13:1048–57.
- [4] Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, et al. *Clostridium difficile* infection in Europe: a hospital-based survey. *Lancet* 2011;377:63–73.
- [5] Davies KA, Longshaw CM, Davis GL, Bouza E, Barbut F, Barna Z, et al. Underdiagnosis of *Clostridium difficile* across Europe: the European, multicentre, prospective, biannual, point-prevalence study of *Clostridium difficile* infection in hospitalised patients with diarrhoea (EUCLID). *Lancet Infect Dis* 2014;14:1208–19.
- [6] Davies KA, Ashwin H, Longshaw CM, Burns DA, Davis GL, Wilcox MH, EUCLID study group. Diversity of *Clostridium difficile* PCR ribotypes in Europe: results from the European, multicentre, prospective, biannual, point-prevalence study of *Clostridium difficile* infection in hospitalised patients with diarrhoea (EUCLID), 2012 and 2013. *Euro Surveill* 2016;21.
- [7] van Dorp SM, Kinross P, Gastmeier P, Behnke M, Kola A, Delmée M, et al. Standardised surveillance of *Clostridium difficile* infection in European acute care hospitals: a pilot study, 2013. *Euro Surveill* 2016;21.
- [8] Crobach MJ, Planché T, Eckert C, Barbut F, Terveer EM, Dekkers OM, et al. European Society of clinical microbiology and infectious Diseases: update of the diagnostic guidance document for *Clostridium difficile* infection. *Clin Microbiol Infect* 2016;22:S63–81.
- [9] Debast SB, Bauer MP, Kuijper EJ, European Society of Clinical Microbiology and Infectious Diseases. European Society of clinical microbiology and infectious Diseases: update of the treatment guidance document for *Clostridium difficile* infection. *Clin Microbiol Infect* 2014;20:1–26.
- [10] Vonberg RP, Kuijper EJ, Wilcox MH, Barbut F, Tüll P, Gastmeier P, et al. Infection control measures to limit the spread of *Clostridium difficile*. *Clin Microbiol Infect* 2008;14:2–20.
- [11] European Centre for Disease Prevention and Control. European Surveillance of *Clostridium difficile* infections. Surveillance protocol version 2.1. Stockholm: ECDC; 2015.
- [12] Fawley WN, Davies KA, Morris T, Parnell P, Howe R, Wilcox MH, *Clostridium difficile* Ribotyping Network (CDRN) Working Group. Enhanced surveillance of *Clostridium difficile* infection occurring outside hospital, England, 2011 to 2013. *Euro Surveill* 2016;21.
- [13] Hensgens MP, Dekkers OM, Demeulemeester A, Buiting AG, Bloembergen P, van Benthem BH, et al. Diarrhoea in general practice: when should a *Clostridium difficile* infection be considered? Results of a nested case–control study. *Clin Microbiol Infect* 2014;20:O1067–74.
- [14] Bryant K, McDonald LC. *Clostridium difficile* infections in children. *Pediatr Infect Dis J* 2009;28:145–6.
- [15] Wendt JM, Cohen JA, Mu Y, Dumyati GK, Dunn JR, Holzbauer SM, et al. *Clostridium difficile* infection among children across diverse US geographic locations. *Pediatrics* 2014;133:651–8.
- [16] Davies K, Davis G, Barbut F, Eckert C, Petrosillo N, Wilcox MH. Variability in testing policies and impact on reported *Clostridium difficile* infection rates: results from the pilot Longitudinal European *Clostridium difficile* Infection Diagnosis surveillance study (LuCID). *Eur J Clin Microbiol Infect Dis* 2016;35:1949–56.
- [17] European Centre for Disease Prevention and Control. European Surveillance of *Clostridium difficile* infections. Surveillance protocol version 2.3. Stockholm: ECDC; 2017.
- [18] European Centre for Disease Prevention and Control. European Surveillance of *Clostridium difficile* infections. Surveillance protocol version 2.2. Stockholm: ECDC; 2015.
- [19] Tang DM, Urrunaga NH, von Rosenvinge EC. Pseudomembranous colitis: not always *Clostridium difficile*. *Cleve Clin J Med* 2016;83:361–6.
- [20] Kola A, Wiuff C, Åkerlund T, van Benthem BH, Coignard B, Lyytikäinen O, et al. Survey of *Clostridium difficile* infection surveillance systems in Europe, 2011. *Euro Surveill* 2016;21.
- [21] Indra A, Huhulescu S, Schneeweis M, Hasenberger P, Kernbichler S, Fiedler A, et al. Characterization of *Clostridium difficile* isolates using capillary gel electrophoresis-based PCR ribotyping. *J Med Microbiol* 2008;57:1377–82.
- [22] Fawley WN, Knetsch CW, MacCannell DR, Harmanus C, Du T, Mulvey MR, et al. Development and validation of an internationally-standardized, high-resolution capillary gel-based electrophoresis PCR-ribotyping protocol for *Clostridium difficile*. *PLoS One* 2015;10, e0118150.
- [23] Persson S, Torpdahl M, Olsen KE. New multiplex PCR method for the detection of *Clostridium difficile* toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied to a Danish strain collection. *Clin Microbiol Infect* 2008;14:1057–64 (Erratum in *Clin Microbiol Infect* 2009;15:296.).
- [24] Paltansing S, van den Berg RJ, Guseinova RA, Visser CE, van der Vorm ER, Kuijper EJ. Characteristics and incidence of *Clostridium difficile*-associated disease in The Netherlands, 2005. *Clin Microbiol Infect* 2007;13:1058–64.
- [25] EUCAST: Clinical breakpoints [Internet]. Available at: http://www.eucast.org/clinical_breakpoints/. Accessed 31 July 2017.
- [26] Freeman J, Vernon J, Morris K, Nicholson S, Todhunter S, Longshaw C, et al. Pan-European longitudinal surveillance of antibiotic resistance among prevalent *Clostridium difficile* ribotypes. *Clin Microbiol Infect* 2015;21. 248.e9–248.e16.
- [27] Debast SB, Bauer MP, Sanders IM, Wilcox MH, Kuijper EJ, ECDC Study Group. Antimicrobial activity of LFF571 and three treatment agents against *Clostridium difficile* isolates collected for a pan-European survey in 2008: clinical and therapeutic implications. *J Antimicrob Chemother* 2013;68:1305–11.
- [28] Baines SD, O'Connor R, Freeman J, Fawley WN, Harmanus C, Mastrantonio P, et al. Emergence of reduced susceptibility to metronidazole in *Clostridium difficile*. *J Antimicrob Chemother* 2008;62:1046–52.
- [29] Widmer AF, Frei R, Erb S, Strandén A, Kuijper EJ, Knetsch CW, et al. Transmissibility of *Clostridium difficile* without contact isolation: results from a prospective observational study with 451 patients. *Clin Infect Dis* 2017;64:393–400.
- [30] Eyre DW, Cule ML, Wilson DJ, Griffiths D, Vaughan A, O'Connor L, et al. Whole genome sequencing reveals diverse sources for *C. difficile* infection. *N Engl J Med* 2013;369:1195–205.
- [31] Eyre DW, Fawley WN, Rajgopal A, Settle C, Mortimer K, Goldenberg SD, et al. Comparison of control of *Clostridium difficile* infection in six English hospitals using whole-genome sequencing. *Clin Infect Dis* 2017;65:433–41.
- [32] Knetsch CW, Connor TR, Mutreja A, van Dorp SM, Sanders IM, Browne HP, et al. Whole genome sequencing reveals potential spread of *Clostridium difficile* between humans and farm animals in The Netherlands, 2002 to 2011. *Euro Surveill* 2014;19:20954.
- [33] Cairns MD, Preston MD, Hall CL, Gerding DN, Hawkey PM, Kato H, et al. Comparative genome analysis and global phylogeny of the toxin variant

- Clostridium difficile* PCR ribotype 017 reveals the evolution of two independent sublineages. J Clin Microbiol 2017;55:865–76.
- [34] He M, Miyajima F, Roberts P, Ellison L, Pickard DJ, Martin MJ, et al. Emergence and global spread of epidemic healthcare-associated *Clostridium difficile*. Nat Genet 2013;45:109–13.
- [35] Barbut F, Delmée M, Brazier JS, Petit JC, Poxton IR, Rupnik M, et al. A European survey of diagnostic methods and testing protocols for *Clostridium difficile*. Clin Microbiol Infect 2003;9:989–96.
- [36] European Centre for Disease Prevention and Control. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals. Stockholm: ECDC; 2013.
- [37] Kuijper EJ, Barbut F, Brazier JS, Kleinkauf N, Eckmanns T, Lambert ML, et al. Update of *Clostridium difficile* infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill 2008;13. pii: 18942.
- [38] Kuijper EJ, Coignard B, Brazier JS, Suetens C, Drudy D, Wiuff C, et al. Update of *Clostridium difficile*-associated disease due to PCR ribotype 027 in Europe. Euro Surveill 2007;12:E1–2.
- [39] Dingle KE, Didelot XD, Quan TP, Eyre DW, Stoesser N, Golubchik T, et al. Effects of control interventions on *Clostridium difficile* infection in England: an observational study. Lancet Infect Dis 2017;17:411–21.
- [40] Suetens C, Kinross P. News from CDI surveillance across Europe. S306. Amsterdam, The Netherlands: ECCMID; 2016.
- [41] Kinross P, Hajdu A, Rupnik M, Kolman J, Lesinszki V, Pászti J, et al. EU-wide surveillance of *Clostridium difficile* provides opportunity to assess outcomes of *C. difficile* ribotype 027 infections. OS0225. Vienna, Austria: ECCMID; 2017.
- [42] Krutova M, Matejkova J, Drevinek P, Kuijper EJ, Nyc O, Study group. Increasing incidence of *Clostridium difficile* ribotype 001 associated with severe course of the infection and previous fluoroquinolone use in the Czech Republic, 2015. Eur J Clin Microbiol Infect Dis 2017;36:2251–8.
- [43] Crobach MJT, Voor In 't Holt AF, Knetsch CW, van Dorp SM, Bras W, Harmanus C, et al. An outbreak of *Clostridium difficile* infections due to a new PCR ribotype 826: epidemiological and microbiological analyses. Clin Microbiol Infect 2018;24:309.e1–e4.
- [44] van Dorp SM, Smajlović E, Knetsch CW, Notermans DW, de Greeff SC, Kuijper EJ. Clinical and microbiological characteristics of *Clostridium difficile* infection among hospitalized children in The Netherlands. Clin Infect Dis 2017;64:1928.
- [45] van Dorp SM, Notermans DW, Alblas J, Gastmeier P, Mentula S, Nagy E, et al. Survey of diagnostic and typing capacity for *Clostridium difficile* infection in Europe, 2011 and 2014. Euro Surveill 2016;21.
- [46] Fawley WN, Freeman J, Smith C, Harmanus C, van den Berg RJ, Kuijper EJ, et al. Use of highly discriminatory fingerprinting to analyze clusters of *Clostridium difficile* infection cases due to epidemic ribotype 027 strains. J Clin Microbiol 2008;46:954–60.
- [47] van den Berg RJ, Schaap I, Templeton KE, Klaassen CH, Kuijper EJ. Typing and subtyping of *Clostridium difficile* isolates by using multiple-locus variable-number tandem-repeat analysis. J Clin Microbiol 2007;45:1024–8.
- [48] Krutova M, Matejkova J, Kuijper EJ, Drevinek P, Nyc O, Czech *Clostridium difficile* study group. *Clostridium difficile* PCR ribotypes 001 and 176—the common denominator of *C. difficile* infection epidemiology in the Czech Republic, 2014. Euro Surveill 2016;21.
- [49] Kanerva M, Ollgren J, Voipio T, Mentula S, Lyytikäinen O. Regional differences in *Clostridium difficile* infections in relation to fluoroquinolone and proton pump inhibitor use, Finland, 2008–2011. Infect Dis (Lond) 2015;47:530–5.